Xylem Is A Secular Winner On Structurally Improved Portfolio, Analyst Says

Oppenheimer analyst Bryan F.

Oppenheimer analyst Bryan F. Blair upgraded Xylem Inc (NYSE:XYL) to Outperform from Perform and introduced a price target of $118. 

The analyst’s rating upgrade reflects his confidence in Xylem’s structurally improved portfolio, continued beat & raise prospects, and medium-term growth prospects.

The analyst views other trading headwinds as largely transitory and says that combined Xylem–Evoqua operations can drive profitable growth over the coming years.

Also ReadXylem And Evoqua Merger: The Blueprint For Leading Global Smart Water Infrastructure, Predicts Analyst

The analyst projects steady top-line and cash flow growth going forward, given Xylem’s backlog of ~$5.3 billion, resilient core WI demand, and benefit from a notably long tail for AMI adoption.

The analyst revised EPS to $3.67 (from $3.70) in FY23 and $4.12 (from $4.20) for FY24. He introduced FY25 EPS of $4.65 with expected revenue synergies (and related incremental drop-through), driving solid upside vs. 2024-25 projections.

Price Action: XYL shares are trading higher by 2.16% at $92.29 on the last check Thursday.

Total
0
Shares
Related Posts
Read More

RxSight, Inc. Announces Preliminary Unaudited Q4 And FY23 Financial And Operational Results And 2024 Guidance; Sees Q4 Revenue $28.6M Vs $25.76M Est.; Sees FY23 Revenue $89.1M Vs $86.34M Est.; Sees FY24 Revenue $128M-$135M Vs $121.48M Est.

RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational

RXST